Patient characteristics
ONCOLOGY
A total of 28 patients were screened for eligibility between August 2020 and March 2022. Of these, 18 female patients with HR‐positive, HER2‐negative ABC were enrolled and treated with HS‐10352 (Figure Study flowchart.Baseline patient characteristics.Abbreviations: BMI, body mass index; CDK, cyclin‐dependent kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; HDAC, histone deacetylase; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SD, standard deviation.PIK3CA mutation confirmed by the central laboratory.PIK3CA mutation confirmed by the central laboratory or past medical records.Others included one case of BEBT‐209, a novel CDK4/6 inhibitor being investigated in clinical trials, and one case of unknown medication.